Spontaneous Regression of Neuroblastoma: An Experimental Approach

References

• Pillemer L, Blum L, Lepow I H, Ross O A, Todd E W, Wardlaw A C. The properdin system and immunity I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954; 120: 279–85
   PubMed Web of Science ®Google Scholar
• Pillemer L. The nature of the properdin system and its interaction with polysaccharide complexes. Ann NY Acad Sci 1956; 66: 233–43
   Web of Science ®Google Scholar
• Wells H. Chemical Pathology. Saunders, Philadelphia 1925
   Google Scholar
• Glumac G, Mates A, Eidinger D. The heterocytotoxicity of human serum III. Studies of the serum levels and distribution of activity in human populations. Clin Exp Immunol 1976; 26: 601–8
   PubMed Web of Science ®Google Scholar
• Bolande R P, Todd E W. The cytotoxic action of normal human serum on certain cells propagated in vitro. AMA Arch Pathol 1958; 66: 720–32
   PubMedGoogle Scholar
• Bolande R P. Cytotoxic action of human serum on atypical mammalian cell lines. Lab Invest 1960; 9: 475–89
   Web of Science ®Google Scholar
• Müller-Eberhard H J. Complement. Annu Rev Biochem 1975; 44: 697–724
   PubMed Web of Science ®Google Scholar
• Bolande R P. Developmental pathology. Am J Pathol 1979; 94: 623–83
   PubMed Web of Science ®Google Scholar
• Bolande R P. Spontaneous regression and cytodifferentiation of cancer in early life: The oncogenic grace period. Surv Synth Pathol Res 1985; 4: 296–311
   PubMedGoogle Scholar
• Eidinger D, Gery I, Bello E. The heterocytotoxicity of human serum II. The role of natural antibody and of the classical and alternative complement pathways. Cell Immunol 1977; 29: 187–94
   PubMed Web of Science ®Google Scholar
• Laskov R, Simon E, Gross J. Studies on a naturally occurring antibody against mouse Landschutz ascites tumor cells. Cytotoxicity assay and quantitation in normal sera. Int J Cancer 1968; 3: 96–105
   PubMed Web of Science ®Google Scholar
• Laskov R, Simon E, Ram D, Gross J. Studies of a naturally occurring human antibody against mouse Landschutz ascites tumor cells II. Identification of the antibody as IgM and its partial purification. Int J Cancer 1968; 3: 107–15
   PubMed Web of Science ®Google Scholar
• Laskov R, Simon E, Gross J. Studies of a naturally occurring human antibody against mouse Landschutz ascites tumor cells III. The nature of the antigenic site on the tumor cell. Int J Cancer 1968; 3: 511–22
   PubMed Web of Science ®Google Scholar
• Violand B N, Racker E. Permeabilization of Ehrlich ascites tumor by human serum. Cell Immunol 1981; 61: 213–9
   PubMed Web of Science ®Google Scholar
• Gross J, Simon E, Szwarc-Bilotynski L, Durst A, Pfefferman R, Polishuk Z. Complement-dependent lysis of Ehrlich ascites cells by human serum (ascitolysin) is lowered in cancer patients and raised in pregnant women. Eur J Cane Clin Oncol 1986; 22: 13–9
   PubMedGoogle Scholar
• Bolande R P, Arnold J L, Mayer D C. Natural cytotoxicity of human serum. A natural IgM “antibody” sensitizes transformed murine cells to the lytic action of complement. Pathol Immunopathol Res 1989; 8: 46–60
   PubMed Web of Science ®Google Scholar
• Bolande R P, Mayer D C. Isolation of a natural cytotoxic IgM “antibody” in human serum sensitizing L cells to complement. Proc Soc Exp Biol Med 1989; 191: 387–90
   PubMed Web of Science ®Google Scholar
• Bolande R P, Mayer D C. The cytolysis of human neuroblastoma cells by a natural IgM “antibody” complement system in pregnancy serum: A mechanism for spontaneous regression. Cancer Invest
   Google Scholar
• Kemshead J T. Monoclonal antibodies to the small round cell tumors of childhood: An international workshop. Prog Clin Biol Res 1988; 271: 535–48
   PubMedGoogle Scholar
• Kemshead J. An international study of the reactivity of a panel of monoclonal antibodies to neuroblastoma and related tumors. William Guy Forbeck Foundation, Hilton Head, SC 1988
   Google Scholar
• Cheung N K, Saarinen U M, Neely J E, Landmeier B, Donovan D, Coccia P F. Monoclonal antibodies to a glycolipid antigen of human neuroblastoma cells. Cancer Res 1985; 45: 2642–9
   PubMed Web of Science ®Google Scholar
• Saarinen U M, Coccia P F, Gerson S L, Peeley R, Cheung N K. Eradication of neuroblastoma cells in vitro by monoclonal antibodies and complement: Method for purging autologous bone marrow. Cancer Res 1985; 45: 5969–75
   PubMed Web of Science ®Google Scholar
• Hellström I, Hellström K E, Bill A H, Pierce G E, Yang J P. Studies on cellular immunity to human neuroblastoma cells. Int J Cancer 1970; 6: 172–88
   PubMed Web of Science ®Google Scholar
• Hellström K E, Hellström I. Spontaneous tumor regression: Possible relationships to in vitro parameters of tumor immunity. Natl Cancer Inst Monogr 1976; 44: 131–4
   PubMedGoogle Scholar
• Miller R W. Ethnic differences in cancer occurrence: Genetic and environmental influences. Prog Cancer Res Ther 1977; 3: 1–14
   Google Scholar
• Medof M E, Walter E I, Rutgers J L, Knowles D M, Nussenzweig V. Identification of the complement decay accelerating factor (DAF) in epithelium and glandular cells and in body fluids. J Exp Med 1987; 165: 848–64
   PubMed Web of Science ®Google Scholar
• Panneerselvam M, Welt S, Old L J, Vogel C W. A molecular mechanism of complement resistance of human melanoma cells. J Immunol 1986; 136: 2534–41
   PubMed Web of Science ®Google Scholar